The prognostic impact of lymphovascular invasion for upper urinary tract urothelial carcinoma: A propensity score-weighted analysis

• Published in: Medicine (Baltimore) Vol. 102; no. 15; p. e33485
• Main Authors: Chang, Yin Lun, Chen, Yen Ta, Wang, Hung Hen, Chiang, Po Hui, Cheng, Yuan Tso, Kang, Chih Hsiung, Chuang, Yao Chi, Lee, Wei Chin, Yang, Wen Chou, Liu, Hui Ying, Su, Yu Li, Huang, Chun Chieh, Tse, Sung Min, Luo, Hao Lun
• Format: Journal Article
• Language: English
• Published: United States Lippincott Williams & Wilkins 14.04.2023
• Subjects: Carcinoma, Transitional Cell - pathology; Humans; Kidney Neoplasms - pathology; Kidney Pelvis - pathology; Nephrectomy; Observational Study; Prognosis; Propensity Score; Retrospective Studies; Ureteral Neoplasms - pathology; Urinary Bladder Neoplasms - surgery
• ISSN: 0025-7974; 1536-5964
• DOI: 10.1097/MD.0000000000033485

Lymphovascular invasion (LVI) predicts poor survival in patients with pathologically localized or locally advanced upper urinary tract urothelial carcinoma (UT-UC). However, LVI is associated with high tumor grade, tumor necrosis, advanced tumor stage, tumor location, concomitant carcinoma in situ, lymph node metastasis, and sessile tumor architecture. These factors might interfere with the analysis of the impact of LVI on oncological prognosis. To address this, this study aimed to clarify the relationship between LVI and patient prognosis in UT-UC using propensity score weighting. Data were collected from 789 patients with UT-UC treated with radical nephroureterectomy without chemotherapy. We evaluated the significance of LVI in predicting metastasis-free survival (MFS), cancer-specific survival (CSS), and overall survival (OS) using propensity score weighting. All weighted baseline characteristics included in the propensity score model were balanced between the LVI (+) and LVI (−) groups. The MFS, CSS, and OS were all significantly poorer in the LVI (+) group. For patients without LVI, the 5-year MFS, CSS, and OS rates were 65.3%, 73.1%, and 67.3%, respectively, whereas the corresponding rates were 50.2%, 63.8 %, and 54.6%, respectively, for patients with LVI. (all P < .001). For patients without LVI, the 10-year MFS, CSS, and OS rates were 61.5%, 69.6%, and 59.2%, respectively, whereas those for patients with LVI were 44.5%, 57.0%, and 42.7%, respectively (all P < .001). LVI is an important pathological feature that predicts metastasis development and worse survival outcome after radical surgery in UT-UC patients.